Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVKD NASDAQ:PRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$5.05-4.2%$5.83$4.21▼$16.25$14.50M1.8173,625 shs47,757 shsPREPrenetics Global$15.61-11.3%$18.82$5.58▼$23.63$263.40M0.15196,132 shs384,001 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics0.00%-17.08%+4.12%-8.68%-64.29%PREPrenetics Global0.00%-3.40%-12.99%-28.95%+169.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$5.05-4.2%$5.83$4.21▼$16.25$14.50M1.8173,625 shs47,757 shsPREPrenetics Global$15.61-11.3%$18.82$5.58▼$23.63$263.40M0.15196,132 shs384,001 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics0.00%-17.08%+4.12%-8.68%-64.29%PREPrenetics Global0.00%-3.40%-12.99%-28.95%+169.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVKDCadrenal Therapeutics 2.00Hold$13.00157.43% UpsidePREPrenetics Global 2.50Moderate Buy$32.33107.13% UpsideCurrent Analyst Ratings BreakdownLatest PRE and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026PREPrenetics Global Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026CVKDCadrenal Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$32.00 ➝ $13.003/16/2026PREPrenetics Global Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$29.00(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVKDCadrenal TherapeuticsN/AN/AN/AN/A$0.63 per shareN/APREPrenetics Global$92.39M2.85N/AN/A$9.27 per share1.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVKDCadrenal Therapeutics-$13.24M-$5.63N/AN/AN/AN/A-411.03%-275.61%N/APREPrenetics Global-$37.71M-$4.02N/AN/AN/A-61.33%-19.61%-15.33%N/ALatest PRE and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51-$1.04+$0.47-$1.04N/AN/A3/31/2026Q4 2025CVKDCadrenal Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A2/18/2026Q4 2025PREPrenetics Global-$0.49-$0.27+$0.22-$1.75$36.15 million$36.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVKDCadrenal TherapeuticsN/AN/AN/AN/AN/APREPrenetics GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVKDCadrenal TherapeuticsN/A2.682.68PREPrenetics GlobalN/A2.972.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVKDCadrenal Therapeutics7.92%PREPrenetics Global25.01%Insider OwnershipCompanyInsider OwnershipCVKDCadrenal Therapeutics26.09%PREPrenetics Global7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVKDCadrenal Therapeutics42.87 million2.12 millionNot OptionablePREPrenetics Global116.87 million15.56 millionNot OptionablePRE and CVKD HeadlinesRecent News About These CompaniesPrenetics Global Ltd (PRE) Q1 2026 Earnings Call Highlights: Record Revenue Surge Amid ...May 15 at 1:09 PM | finance.yahoo.comPrenetics Global Q1 Earnings Call HighlightsMay 14 at 3:04 PM | marketbeat.comPrenetics Global Limited Class AMay 14 at 2:57 PM | edition.cnn.comPrenetics Lifts 2026 IM8 Revenue Outlook on Record Q1 Growth and Asset DivestitureMay 14 at 8:31 AM | tipranks.comPrenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8May 14 at 8:05 AM | globenewswire.comPrenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210MMay 14 at 8:00 AM | globenewswire.comPrenetics Global Limited to Announce Q1 2026 Financial Results on May 14, 2026May 8, 2026 | quiverquant.comQPrenetics to Report Q1 2026 Financial Results on May 14, 2026 and Host Earnings Conference CallMay 8, 2026 | globenewswire.comPrenetics’ IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year PartnershipMay 7, 2026 | markets.businessinsider.comPrenetics' IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year PartnershipMay 7, 2026 | globenewswire.comPrenetics Global (PRE) Projected to Post Earnings on ThursdayMay 7, 2026 | marketbeat.comPrenetics to Exit Bitcoin Holdings and Reinvest Up to $40 Million in Core IM8 Health BusinessMay 6, 2026 | theglobeandmail.comPrenetics Global (NASDAQ:PRE) Trading Up 1.9% - Should You Buy?May 2, 2026 | marketbeat.comPrenetics Global Ltd.April 23, 2026 | barrons.comPrenetics Global Ltd. WtApril 17, 2026 | barrons.comPrenetics’ IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year OneApril 14, 2026 | markets.businessinsider.comPrenetics Global Limited Warrant (PRENW) Real TimeApril 11, 2026 | nasdaq.comInitiating Coverage of Rapid-Growing PREApril 8, 2026 | finance.yahoo.comPrenetics Brings Giannis Antetokounmpo Onboard as IM8 Global Partner and ShareholderApril 8, 2026 | theglobeandmail.comPrenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year PartnershipApril 2, 2026 | markets.businessinsider.com7 fastest growing Asian stocks to buyApril 2, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRE and CVKD Company DescriptionsCadrenal Therapeutics NASDAQ:CVKD$5.05 -0.22 (-4.17%) Closing price 05/15/2026 03:59 PM EasternExtended Trading$5.10 +0.04 (+0.89%) As of 05/15/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Prenetics Global NASDAQ:PRE$15.61 -1.98 (-11.26%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$16.12 +0.51 (+3.29%) As of 05/15/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
